Daiichi Sankyo Case: Supreme Court Reserves Order On Plea Against Singh Brothers
The Supreme Court on Thursday reserved its order on a contempt plea filed by Japanese pharma company Daiichi Sankyo against the Ranbaxy's Singh brothers over non-payment of Rs 3,500 crore in an international arbitration award.
The bench headed by Chief Justice Ranjan Gogoi said it will decide on the issue of "contempt of court" only.
Senior advocate Fali Nariman appearing for Daiichi told the SC that former Ranbaxy promoter Malvinder Singh had given an undertaking in the Delhi High Court that the value of their "unencumbered assets" was Rs 452 crore.
Mr Nariman said the Delhi HC-appointed valuer had prepared two reports. Counsel for Malvinder Singh told the court that the enforcement proceedings against them are still pending before the HC, and that all the bank accounts have already been frozen by the court. His counsel said it is a civil contempt case, and Mr Malvinder hasn't violated any court order.
Shivinder Singh, brother of Malvinder, through his counsel, told the court the current contempt emerges for not following an interim order. During the hearing, Mr Malvinder presenting his point regarding the allegations of violating restraint on dealing with Fortis shares, said: "I didn't violate restraint on dealing with Fortis' shares, Indiabulls did that."
On March 14, the top court had asked the two to submit a concrete plan for repaying the Japanese firm in consultation with their accountants and financial/legal advisors and then inform the court on April 5. But, the bench noticed that no payback plan has been put in place.
Malvinder's counsel had told the court that they have been duped and "nearly Rs 6,300 crore has been siphoned".
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.